Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
NCT02495103 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2021-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All subjects are off-study.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SRC within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-12-30Results posted on the registry: Pfizer, Bosutinib (NCT02228382)
- 2021-12-30Also stopped (terminated): Pfizer, Bosutinib (NCT02228382)
- 2021-11-01Results posted on the registry: Ronald Weigel, Vandetanib (NCT01934335)
- 2021-11-01Also stopped (terminated): Ronald Weigel, Vandetanib (NCT01934335)
- 2021-10-07Results posted on the registry: Cancer Research UK, Vandetanib, Selumetinib + Vandetanib, Selumetinib (NCT01586624)
- 2021-09-27Also stopped (terminated): Pfizer, Bosutinib + Letrozole (NCT00880009)
- 2021-08-17Results posted on the registry: Pfizer, bosutinib (NCT01903733)
- 2021-07-21Phase 3 first posted: Novartis Pharmaceuticals, Imatinib + Nilotinib (NCT04971226)
- 2021-07-14Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Lenvatinib + Sorafenib (NCT03630120)
- 2021-06-30Results posted on the registry: University of Washington, Gene Expression Analysis + Genetic Variation Analysis (NCT02551718)
- 2021-02-18Phase 3 first posted: Hoffmann-La Roche, Pralsetinib + Cabozantinib (NCT04760288)
- 2021-02-03Results posted on the registry: Boston Scientific Corporation, BTG-002814 (NCT03291379)
- 2021-01-22Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Lenvatinib + Sorafenib (NCT03630120)
- 2021-01-22Results posted on the registry: Fox Chase Cancer Center, Vandetanib + 5 Fluorouracil (FU) (NCT01183559)
- 2021-01-14Results posted on the registry: University of Chicago, vandetanib (NCT01414426)
- 2020-12-22Results posted on the registry: National Cancer Institute (NCI), Vandetanib (NCT00514046)
- 2020-11-24Results posted on the registry: Pfizer, Bosutinib (NCT03128411)
- 2020-11-19Also stopped (terminated): M.D. Anderson Cancer Center, Axitinib + Bosutinib (NCT02782403)
- 2020-11-13Results posted on the registry: Yale University, Saracatinib + Placebos (NCT02955186)
- 2020-11-06Results posted on the registry: National Cancer Institute (NCI), 75 approved agents (NCT02788201)
- 2020-07-30Also stopped (terminated): Baylor College of Medicine, saracatinib (NCT02737202)
- 2020-05-11Also stopped (terminated): M.D. Anderson Cancer Center, Bosutinib (NCT02906696)
- 2020-04-22Results posted on the registry: M.D. Anderson Cancer Center, Bosutinib (NCT02906696)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision